NCT01266174 is a Phase 2 clinical trial of Eltoprazine in Cognitive Impairment, sponsored by Amarantus BioScience Holdings, Inc..

Who is sponsoring NCT01266174?

NCT01266174 is sponsored by Amarantus BioScience Holdings, Inc..

What drugs are being tested in NCT01266174?

Interventions in NCT01266174: Eltoprazine, Placebo.

What condition does NCT01266174 study?

NCT01266174 studies Cognitive Impairment, Schizophrenia.

Is NCT01266174 still recruiting?

NCT01266174 is currently completed. Last updated 13 April 2015.

Last reviewed 2015-04-13 · How we verify

NCT01266174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia

Completed Phase 2 Last updated 13 April 2015

What this trial tests

Phase 2 trial testing Eltoprazine in Cognitive Impairment in 31 participants. Completed in 1 November 2012.

Timeline

1 August 2011

Primary endpoint
1 September 2012

1 November 2012

Quick facts

Lead sponsor	Amarantus BioScience Holdings, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	31
Start date	1 August 2011
Primary completion	1 September 2012
Estimated completion	1 November 2012
Sites	6 locations across United States

Drugs / interventions tested

Eltoprazine — full drug profile →
Placebo

Conditions studied

Cognitive Impairment — all drugs for Cognitive Impairment →
Schizophrenia — all drugs for Schizophrenia →

Sponsor

Amarantus BioScience Holdings, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Cognitive Impairment or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

MATRICS Consensus Cognitive Battery (MCCB)
Time frame: At Baseline and every 4 weeks
Assessment of cognitive effects over time measured suing the MCCB battery

Sponsor's own description

The purpose of this study is to determine if eltoprazine (as an adjunct to anti-psychotic medication) improves one or more aspects of cognitive impairment in adult schizophrenic patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, et al · · 2015 · cited 121× · PMID 25669730 · DOI 10.1093/brain/awu409
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
Wong TS, Li G, Li S, Gao W, et al · · 2023 · cited 113× · PMID 37137892 · DOI 10.1038/s41392-023-01427-2

Verify or expand the search:

Other recruiting trials for Cognitive Impairment

Currently open trials in the same condition.

NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01266174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amarantus BioScience Holdings, Inc.
Last refreshed: 13 April 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01266174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing